Physician profile
Amy Rosen
NPI 1548274574
$960.36
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.93 · 2020: $265 · 2021: $425 · 2022: $13.48 · 2023: $152 · 2024: $89.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $274.67 | 2020-2023 | Mounjaro |
| Abbvie INC. | $94.98 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $92.96 | 2020-2021 | |
| Novo Nordisk INC | $60.02 | 2019-2023 | Wegovy |
| Arbor Pharmaceuticals, INC. | $54.62 | 2021 | |
| Amgen INC. | $54.49 | 2020-2023 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $54.20 | 2020-2023 | Farxiga |
| Allergan, INC. | $42.79 | 2020 | |
| Cvrx, INC. | $41.25 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $28.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.81 | 2021 | |
| Redhill Biopharma INC. | $24.90 | 2020 | |
| Heartflow, INC. | $19.12 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $18.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.63 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $14.97 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $14.22 | 2024 | Opsumit |
| Seqirus USA INC | $13.95 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.